​

Ligand Pharmaceuticals (LGND) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Ligand Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$268.09M

Latest Revenue (Q)

$115.46M

Main Segment (Y)

Royalty

Ligand Pharmaceuticals Revenue by Period

Ligand Pharmaceuticals Revenue by Year

DateRevenueChange
2025-12-31$268.09M60.40%
2024-12-31$167.13M27.28%
2023-12-31$131.31M-33.09%
2022-12-31$196.25M-18.75%
2021-12-31$241.54M47.68%
2020-12-31$163.56M35.98%
2019-12-31$120.28M-52.17%
2018-12-31$251.45M78.21%
2017-12-31$141.10M29.48%
2016-12-31$108.97M51.53%
2015-12-31$71.91M11.43%
2014-12-31$64.54M31.78%
2013-12-31$48.97M56.03%
2012-12-31$31.39M4.50%
2011-12-31$30.04M27.61%
2010-12-31$23.54M-39.55%
2009-12-31$38.94M42.56%
2008-12-31$27.32M111.84%
2007-12-31$12.89M-90.85%
2006-12-31$140.96M-20.18%
2005-12-31$176.61M8.01%
2004-12-31$163.51M15.85%
2003-12-31$141.14M46.05%
2002-12-31$96.64M26.59%
2001-12-31$76.34M58.68%
2000-12-31$48.11M17.63%
1999-12-31$40.90M131.07%
1998-12-31$17.70M-65.76%
1997-12-31$51.70M40.49%
1996-12-31$36.80M50.20%
1995-12-31$24.50M84.21%
1994-12-31$13.30M-

Ligand Pharmaceuticals generated $268.09M in revenue during NA 2025, up 60.40% compared to the previous quarter, and up 163.91% compared to the same period a year ago.

Ligand Pharmaceuticals Revenue by Quarter

DateRevenueChange
2025-09-30$115.46M142.43%
2025-06-30$47.63M5.06%
2025-03-31$45.33M5.89%
2024-12-31$42.81M-17.37%
2024-09-30$51.81M24.76%
2024-06-30$41.53M34.07%
2024-03-31$30.98M10.24%
2023-12-31$28.10M-14.50%
2023-09-30$32.87M24.66%
2023-06-30$26.37M-40.05%
2023-03-31$43.98M62.61%
2022-12-31$27.05M-54.33%
2022-09-30$59.22M18.14%
2022-06-30$50.13M37.27%
2022-03-31$36.52M-49.61%
2021-12-31$72.47M11.78%
2021-09-30$64.83M-23.43%
2021-06-30$84.67M53.54%
2021-03-31$55.15M-21.20%
2020-12-31$69.99M67.25%
2020-09-30$41.85M1.03%
2020-06-30$41.42M24.91%
2020-03-31$33.16M22.80%
2019-12-31$27.00M8.85%
2019-09-30$24.81M-0.72%
2019-06-30$24.99M-42.54%
2019-03-31$43.48M-27.03%
2018-12-31$59.59M30.50%
2018-09-30$45.66M-49.29%
2018-06-30$90.04M60.34%
2018-03-31$56.16M11.28%
2017-12-31$50.46M51.20%
2017-09-30$33.38M19.22%
2017-06-30$28.00M-4.35%
2017-03-31$29.27M-23.35%
2016-12-31$38.19M76.63%
2016-09-30$21.62M10.75%
2016-06-30$19.52M-34.16%
2016-03-31$29.65M39.90%
2015-12-31$21.19M19.72%
2015-09-30$17.70M-3.89%
2015-06-30$18.42M26.13%
2015-03-31$14.60M-36.51%
2014-12-31$23.00M53.60%
2014-09-30$14.97M41.15%
2014-06-30$10.61M-33.53%
2014-03-31$15.96M8.29%
2013-12-31$14.74M13.32%
2013-09-30$13.01M35.75%
2013-06-30$9.58M-17.78%
2013-03-31$11.65M-14.55%
2012-12-31$13.63M113.88%
2012-09-30$6.38M11.02%
2012-06-30$5.74M1.88%
2012-03-31$5.64M-56.43%
2011-12-31$12.94M125.33%
2011-09-30$5.74M-23.07%
2011-06-30$7.46M91.56%
2011-03-31$3.90M-1.12%
2010-12-31$3.94M-49.50%
2010-09-30$7.80M33.64%
2010-06-30$5.84M-2.01%
2010-03-31$5.96M-57.37%
2009-12-31$13.98M76.90%
2009-09-30$7.90M4.04%
2009-06-30$7.59M-19.81%
2009-03-31$9.47M-23.56%
2008-12-31$12.39M136.07%
2008-09-30$5.25M9.24%
2008-06-30$4.80M-1.44%
2008-03-31$4.87M-15.53%
2007-12-31$5.77M-

Ligand Pharmaceuticals generated $115.46M in revenue during Q3 2025, up 142.43% compared to the previous quarter, and up 278.01% compared to the same period a year ago.

Ligand Pharmaceuticals Revenue Breakdown

Ligand Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 25Dec 24Dec 22Dec 21Dec 20
Royalty, Kyprolis$35.53M$38.38M$30.12M$27.47M-
Royalty, Other$10.37M$8.95M$7.63M$11.38M-
Service$6.81M$25.53M$1.12M$23.71M$21.80M
Royalty, Evomela$5.94M$8.68M$10.20M$10.08M-
Royalty$161.00M$108.77M$72.53M$48.93M-
Material Sales, Captisol, Core$40.21M$30.88M$16.43M--
License Fees$6.99M$1.94M$2.85M$5.08M$4.38M
Intangible Royalty Assets$132.53M$95.33M---
Financial Royalty Assets$28.47M$13.44M---
Contract Revenue$66.87M$27.48M$19.22M$63.96M$42.66M
Material Sales, Captisol-$30.88M$104.50M$164.25M$109.96M
Material Sales, Captisol, COVID--$88.07M--
Milestone--$9.15M$28.75M$11.52M
License Fees, Milestones, and Other Product, Other--$6.11M$6.41M$4.97M

Ligand Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 25: Royalty (32.54%), Intangible Royalty Assets (26.79%), Contract Revenue (13.52%), Material Sales, Captisol, Core (8.13%), Royalty, Kyprolis (7.18%), Financial Royalty Assets (5.75%), Royalty, Other (2.10%), License Fees (1.41%), Service (1.38%), and Royalty, Evomela (1.20%).

Quarterly Revenue by Product

Product/ServiceDec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Sep 21Jun 21Mar 21Sep 20Jun 20Mar 20Sep 19Jun 19
Royalty$50.53M$46.59M$36.40M$27.49M$77.06M$31.71M$20.43M$17.15M$21.04M$19.84M$17.96M$13.70M$15.65M$8.62M$7.11M$9.01M$7.18M$6.57M--
Intangible Royalty Assets$40.70M$40.16M$30.08M$21.59M$68.78M$26.55M--------------
Financial Royalty Assets$9.83M$6.42M$6.31M$5.90M$8.29M$5.16M--------------
Contract Revenue$66.74M$131.00K$716.00K$16.20M$-20.87M$10.30M$9.91M$19.88M$14.09M$13.55M$16.77M$9.45M$5.19M$2.13M------
Material Sales, Captisol-$10.67M$8.29M$13.46M$24.63M$6.25M$5.22M$10.62M$26.88M$35.95M$29.55M$12.12M$35.09M$62.51M$31.27M$23.39M----
Kyprolis-$11.62M$8.80M$4.72M$11.60M$8.10M$6.23M$9.12M$7.13M$4.62M$8.82M$5.44M$4.29M$6.92M$5.48M$4.41M----
Evomela-$1.89M$1.47M$1.98M$1.75M$2.36M$2.55M$3.12M$2.39M$2.70M$2.67M$2.19M$2.33M$1.80M$1.20M$1.58M----
Rylaze-$3.56M$2.86M$3.12M$3.89M$3.03M$2.61M$2.10M$2.32M$1.65M----------
Teriparatide Injection-$2.63M$2.30M$1.19M$2.38M$3.61M$3.50M$4.07M$5.50M$2.91M----------
Royalty, Other----$6.67M$2.27M$3.33M$2.27M$3.78M$1.42M$619.00K$1.81M$4.16M$983.00K$492.00K$280.00K$501.00K$584.00K--
License Fees------$508.00K$114.00K$-2.31M$460.00K$1.61M$3.09M$200.00K$1.05M$1.04M$158.00K----
License Fees, Milestones, and Product, Other, Product, Other------$208.00K$789.00K$1.21M$1.58M$2.56M$1.65M$1.54M$1.84M$995.00K-----
Material Sales, Captisol, COVID--------$23.58M$32.37M$26.22M$5.90M--------
Material Sales, Captisol, Core------$5.22M$10.62M$3.30M$3.58M$3.33M$6.23M--------
Milestone-------$15.30M$-4.87M$3.66M$1.27M$9.09M$7.42M$3.60M$8.42M$960.00K----
Contract Revenue, Service---------$4.97M$5.45M$5.15M$4.83M$7.36M$5.46M$7.34M----
Promacta--------------------
Service----------------$4.58M$3.36M--
MilestoneMember----------------$3.47M$334.00K--
MaterialSalesCaptisolMember----------------$24.47M$21.11M--
LicenseFeesMilestonesandProductOtherProductOtherMember----------------$1.06M$821.00K--
LicenseFeesMember----------------$660.00K$975.00K--

Ligand Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Dec 25: Contract Revenue (39.77%), Royalty (30.11%), Intangible Royalty Assets (24.26%), and Financial Royalty Assets (5.86%).

Ligand Pharmaceuticals Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
ACADACADIA Pharmaceuticals$957.80M$278.63M
MIRMMirum Pharmaceuticals$521.31M$133.01M
ADMAADMA Biologics$510.17M$134.22M
LGNDLigand Pharmaceuticals$268.09M$115.46M
SLNOSoleno Therapeutics$190.41M$66.02M
NAMSNewAmsterdam Pharma$22.50M$19.14M
CRNXCrinetics Pharmaceuticals$5.42M$143.00K
VKTXViking Therapeutics--
DYNDyne Therapeutics--
PRAXPraxis Precision Medicines--
BLTEBelite Bio--

LGND Revenue FAQ

What is Ligand Pharmaceuticals’s yearly revenue?

Ligand Pharmaceuticals's yearly revenue for 2025 was $268.09M, representing an increase of 60.40% compared to 2024. The company's yearly revenue for 2024 was $167.13M, representing an increase of 27.28% compared to 2023. LGND's yearly revenue for 2023 was $131.31M, representing a decrease of -33.09% compared to 2022.

What is Ligand Pharmaceuticals’s quarterly revenue?

Ligand Pharmaceuticals's quarterly revenue for Q3 2025 was $115.46M, a 142.43% increase from the previous quarter (Q2 2025), and a 122.85% increase year-over-year (Q3 2024). The company's quarterly revenue for Q2 2025 was $47.63M, a 5.06% increase from the previous quarter (Q1 2025), and a 14.68% increase year-over-year (Q2 2024). LGND's quarterly revenue for Q1 2025 was $45.33M, a 5.89% increase from the previous quarter (Q4 2024), and a 46.34% increase year-over-year (Q1 2024).

What is Ligand Pharmaceuticals’s revenue growth rate?

Ligand Pharmaceuticals's revenue growth rate for the last 3 years (2023-2025) was 104.16%, and for the last 5 years (2021-2025) was 10.99%.

What are Ligand Pharmaceuticals’s revenue streams?

Ligand Pharmaceuticals's revenue streams in c 25 are Royalty, Kyprolis, Royalty, Other, Service, Royalty, Evomela, Royalty, Material Sales, Captisol, Core, License Fees, Intangible Royalty Assets, Financial Royalty Assets, and Contract Revenue. Royalty, Kyprolis generated $35.53M in revenue, accounting 7.18% of the company's total revenue, down -7.41% year-over-year. Royalty, Other generated $10.37M in revenue, accounting 2.10% of the company's total revenue, up 15.89% year-over-year. Service generated $6.81M in revenue, accounting 1.38% of the company's total revenue, down -73.32% year-over-year. Royalty, Evomela generated $5.94M in revenue, accounting 1.20% of the company's total revenue, down -31.53% year-over-year. Royalty generated $161M in revenue, accounting 32.54% of the company's total revenue, up 48.02% year-over-year. Material Sales, Captisol, Core generated $40.21M in revenue, accounting 8.13% of the company's total revenue, up 30.21% year-over-year. License Fees generated $6.99M in revenue, accounting 1.41% of the company's total revenue, up 259.47% year-over-year. Intangible Royalty Assets generated $132.53M in revenue, accounting 26.79% of the company's total revenue, up 39.03% year-over-year. Financial Royalty Assets generated $28.47M in revenue, accounting 5.75% of the company's total revenue, up 111.75% year-over-year. Contract Revenue generated $66.87M in revenue, accounting 13.52% of the company's total revenue, up 143.38% year-over-year.

What is Ligand Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 25, the largest source of revenue of Ligand Pharmaceuticals was Royalty. This segment made a revenue of $161M, representing 32.54% of the company's total revenue.